

Product News

Lonza to Present New Technologies and Products for Advancing Stem Cell Research and Discovery at ISSCR 2015

Cologne, Germany / Walkersville, MD, USA, 26 May 2015 – Lonza has announced that it will be showcasing three new products for stem cell researchers at the upcoming International Society for Stem Cell Research (ISSCR) Annual Meeting (Stockholm, Sweden, 24 to 27 June 2015), through poster presentations, as part of an Innovation Showcase session and at its exhibition booth at the event.

These new innovations include an updated version of Lonza's L7™ hiPSC Reprogramming and hPSC Culture System, which now includes the option to select specific reagents and protocols for reprogramming peripheral blood mononuclear cells (PBMCs). Lonza will also showcase the CytoSMART™ Live Cell Imaging System, an innovative, cost-effective tool for remotely monitoring and analyzing cell cultures. In addition, it will provide a preview of the upcoming RAFT™ Collagen-Based 3D Cell Culture System for growing and studying cells in a more *in vivo*-like environment.

Lonza's Innovation Showcase session will be held on 25 June 2015 (11:30 to 12:30 in Room A4) and is entitled "Smart Technologies for Advancing Stem Cell Research and Discoveries." It will include three presentations:

- **"The Generation of Down Syndrome iPSC Cells Using Infant Blood with Lonza's L7™ Reprogramming and Culture System,"** by Pollyanna Goh, Ph.D., Post-Doctoral Research Associate, Centre for Genomics and Child Health, Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London.
- **"CytoSMART™ Live Cell Imaging System for Real-Time Evaluation of Human iPSC Cultivation and Maintenance within a cGMP Compliant Process,"** by Behnam Ahmadian, Ph.D., Lonza Walkersville, Inc., Senior Manager, Scientific PSC Programs.
- **"RAFT™: A Bio-Mimetic 3D Culture Method for PSC Hepatocyte Differentiation, Maturation, and Modelling of *In Vivo* Systems,"** by Richard L. Gieseck III, Ph.D. Candidate, NIH-Cambridge Scholar, Wellcome Trust-Medical Research Council Stem Cell Institute, Anne McLaren Laboratory for Regenerative Medicine, Department of Surgery, University of Cambridge.

A number of researchers who are currently collaborating with Lonza will also be presenting posters at ISSCR, demonstrating the effective use of Lonza's L7™ System across a range of experimental applications. These posters can be viewed in Exhibition Hall B during the poster presentation reception sessions scheduled each evening between approximately 18.00 and 20.00.

Product News

Dr. Minh Hong, Marketing Manager for Bioscience Solutions at Lonza Walkersville, Inc, said: “hiPSCs are a powerful tool for use across a range of primary research and therapeutic applications. However, they can be challenging to generate and nurture. The new products we’ll be showcasing at ISSCR have been explicitly developed to make reprogramming, proliferation, and downstream experiments simpler, easier and more effective. As part of our wider cell culture product portfolio, they demonstrate Lonza’s ongoing commitment to provide researchers with expert tools, designed to drive discovery.”

Showcasing the Latest Technologies for Supporting Stem Cell Research

In its presentations, Lonza will explain how its latest technological innovations support stem cell research. These include the new [L7™ PBMC Reprogramming Bundle](#), which offers an optimized protocol and new reagents for generating human induced pluripotent stem cells (hiPSCs) from PBMCs, including supportive growth media as well as specific reprogramming enhancers. The new bundle works seamlessly with other elements of the L7™ Workflow: once the hiPSC lines have been created, these can be expanded, passaged and preserved using the existing components of the L7™ System.

The [CytoSMART™ Live Cell Imaging System](#) highlighted in the second presentation is a small, affordable and easy-to-use tool that allows researchers to view and record cell cultures remotely with the CytoSMART™ System via Lonza’s CytoSMART™ Cloud Technology. It is an ideal system for the documentation and monitoring of iPSC generation or for the remote monitoring of stem cells grown under hypoxic conditions.

Lastly, the [RAFT™ 3D Culture System](#) will be previewed at the event ahead of its launch later this year. The system is designed to offer a realistic and reproducible extracellular matrix for cells to grow in. The novel RAFT™ Absorber Technology gently removes media from the culture plate to create high-density cell-seeded collagen gels that mimic the natural *in vivo* environment. It is a highly versatile system available in a number of formats, supporting a wide variety of research applications.

Meet with Lonza at ISSCR 2015

Lonza invites all ISSCR 2015 attendees wishing to learn more about how Lonza’s innovative products can support stem cell research to [visit exhibition booth B04:11](#), attend the showcase session or visit the poster receptions. More information can also be found on the Lonza website: www.lonza.com/isscr.

Product News

About Lonza Pharma&Biotech – Bioscience Solutions

Lonza provides the pharma market with the tools life science researchers use to develop and test therapeutics, from basic research to final product release. Lonza's bioscience products and services range from cell culture and discovery technologies for research, to quality control tests and software to ensure product quality. Lonza Bioscience Solutions serves research customers worldwide in pharmaceutical, biopharmaceutical, biotechnology and personal care companies, as well as academic and government research institutions. The company delivers physiologically relevant cell biology solutions, and complete solutions for rapid microbiology. Primary brands include the BioWhittaker™, Clonetics™, FlashGel™, MetaPhor™, MycoAlert™, Nucleofection™, NuSieve™, PAGER™, Poietics™ and SeaKem® product families.

About Lonza

Lonza is one of the world's leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets. We harness science and technology to create products that support safer and healthier living and that enhance the overall quality of life.

Not only are we a custom manufacturer and developer, Lonza also offers services and products ranging from active pharmaceutical ingredients and stem-cell therapies to drinking water sanitizers, from the vitamin B compounds and organic personal care ingredients to agricultural products, and from industrial preservatives to microbial control solutions that combat dangerous viruses, bacteria and other pathogens.

Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 40 major manufacturing and R&D facilities and approximately 9,800 employees worldwide. The company generated sales of about CHF 3.64 billion in 2014 and is organized into two market-focused segments: Pharma&Biotech and Specialty Ingredients. Further information can be found at www.lonza.com.

Lonza Contact Information

Lonza Group Ltd
Head Investor Relations
Dirk Oehlers
Tel +41 61 316 8540
Fax +41 61 316 9540
dirk.oehlers@lonza.com

Lonza Group Ltd
Head Corporate Communications
Dominik Werner
Tel +41 61 316 8798
Fax +41 61 316 9540
dominik.werner@lonza.com

Lonza Group Ltd
Head External Communications
Constance Ward
Tel +41 61 316 8840
Fax +41 61 316 9840
constance.ward@lonza.com

Additional Information and Disclaimer

Lonza Group Ltd is headquartered in Basel, Switzerland, and is listed on the SIX Swiss Exchange and secondary listed on the Singapore Exchange Securities Trading Limited ("SGX-ST"). Lonza Group Ltd is not subject to the SGX-ST's continuing listing requirements. Lonza Group Ltd is subject to the listing rules of the SIX Swiss Exchange, which does not have specific

Product News

requirements equivalent to the listing rules of the SGX-ST for interested person transactions, acquisition and realizations and delisting.

Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.